Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123171 | 0.86 | PIP4K2A (0.36) | MAP2K1MAPTATMKMT2ASMN1; SMN2 | |
| SCHEMBL3120158 | 0.86 | CLK1 (0.41) | MAP2K1MAP2K2KDM4E | |
| SCHEMBL28777744 | 0.84 | PRMT5 (0.34) | ATM | |
| SCHEMBL4126153 | 0.75 | CLK1 (0.56) | MAPTMAPK1ATMKMT2ASMN1; SMN2 | |
| SCHEMBL23099071 | 0.70 | LIMK1 (0.37) | KDM4E | |
| SCHEMBL3975260 | 0.66 | MAP2K1 (0.70) | MAP2K1MAP2K2 | |
| SCHEMBL949843 | 0.65 | MAP2K1 (0.44) | MAP2K1MAP2K2 | |
| SCHEMBL949141 | 0.65 | MAP2K1 (0.51) | MAP2K1MAP2K2 | |
| SCHEMBL30033040 | 0.65 | MAP2K1 (0.51) | MAP2K1MAP2K2 | |
| SCHEMBL4107958 | 0.65 | MAP2K1 (0.52) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604051-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2013-12-10 | — | — | US | claimed |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2013-06-13 | — | — | US | claimed |
| US-8394822-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-12 | — | — | US | claimed |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2012-12-27 | — | — | US | claimed |
| US-8283359-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2012-10-09 | — | — | US | claimed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | claimed |
| US-8604051-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2013-12-10 | — | — | US | disclosed |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2013-06-13 | — | — | US | disclosed |
| US-8394822-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2012-12-27 | — | — | US | disclosed |
| US-8283359-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2012-10-09 | — | — | US | disclosed |
| CN-101379067-B | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA SA | 2011-03-23 | — | — | CN | disclosed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | disclosed |
| CN-101379067-A | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA SA (BE) | 2009-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | SRC 262/4885MAP2K1 25/4885MAP2K2 11/4885 |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | SRC 262/4885MAP2K1 25/4885MAP2K2 11/4885 |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAPK1, MAP3K6 | SRC 434/4885MAP2K1 4/4885MAP2K2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.